Business Wire

Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Nasdaq:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced it is developing its first adeno-associated ...
Nasdaq

Rocket Pharmaceuticals announces publication of Phase 1 RP-A501 long-term data

Rocket Pharmaceuticals (RCKT) presented long-term safety and efficacy results from the Phase 1 RP-A501 study which showed that RP-A501 was generally well tolerated and all evaluable Danon disease ...
La Grande Observer

Phenomenex Introduces Biozen™ Native RP-1 and RP-5: A Novel Way to Characterize ADCs with Unmatched Throughput and High-Quality Data

“Our team is excited by the advanced ADC characterization capabilities enabled by this new, first of its kind, native reversed phase chromatography product, Biozen Native RP,” says Carl Sanchez, ...
Nasdaq

Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 ...

All six evaluable Phase 1 patients with Danon disease are alive and transplant-free up to age 25 years RP-A501 demonstrated safety and meaningful efficacy; all evaluable patients show cardiac LAMP2 ...
Business Wire

Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of ...

Investor webinar to be held later today at 4:30 p.m. ET CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a ...